Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst
Lucid Diagnostics is likely to gain Medicare reimbursement for EsoGuard testing. Analyst Mike Matson maintains a Buy rating with a $3 price target. Over 25,000 EsoGuard tests completed; reimbursement expected in early 2025. Clinical studies show nearly 100% concordance and negative predictive value. Recent stock offering caused a 6.80% decline in stock price.
View signal analysis